Recent Updates
Recently added Catalysts
SKYE Negative Sentiment

Skye Bioscience, Inc. Class Action: Levi & Korsinsky Reminds Skye Bioscience, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2026 – SKYE

Key Takeaway: Skye Bioscience, Inc. is facing a class action securities lawsuit related to alleged fraud that affected investors between November 4, 2024, and October 3, 2025. The lawsuit claims that the company's lead product candidate, nimacimab, was misrepresented, leading to inflated expectations regarding its efficacy and market prospects. Affected investors have until January 16, 2026, to apply for lead plaintiff status, although compensation may be available without incurring costs. The lawsuit highlights concerns over transparency in the company's communications to investors.
Price reaction · baseline $1.05 (2026-01-08 close) · hit after-hours · 5 other SKYE headline(s) in the window, move may be shared
day 0 close
-6.7%
day 1 · peak
-10.4%
day 3
-2.9%

Market Sentiment Analysis

CONCERNS & RISKS

  • The class action lawsuit indicates potential securities fraud claims against Skye Bioscience.
  • The company's lead product, nimacimab, is alleged to be less effective than previously claimed.
  • Investors may face financial losses due to misleading statements by the company.
  • Deadlines for investor claims may add pressure on affected shareholders.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
24.3%
average across 4 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
Nimacimab
Phase 2 · Obesity

Full Press Release Details

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Skye Bioscience, Inc. ("Skye Bioscience, Inc." or the "Company") (NASDAQ: SKYE) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Skye Bioscience, Inc. investors who were adversely affected by alleged securities fraud between November 4, 2024 and October 3, 2025. Follow the link below to get more information and be contacted by a member of our team:
SKYE investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i)The Company’s lead product candidate, nimacimab, was less effective than defendants had led investors to believe; (ii) accordingly, nimacimab’s clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, defendants’ public statements were materially false and misleading at all relevant times.
WHAT'S NEXT? If you suffered a loss in Skye Bioscience, Inc. during the relevant time frame, you have until January 16, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor

Frequently Asked Questions

What is the lawsuit against Skye Bioscience about?

The lawsuit alleges securities fraud by Skye Bioscience, claiming false statements about the effectiveness of their product nimacimab.

Who can join the class action lawsuit?

Investors who suffered losses in Skye Bioscience between November 4, 2024, and October 3, 2025, can join.

What is the deadline to request lead plaintiff status?

The deadline to request lead plaintiff status is January 16, 2026.

Are there any costs to participate in the lawsuit?

There are no out-of-pocket costs or fees for class members to participate in the lawsuit.

Why choose Levi & Korsinsky for legal representation?

Levi & Korsinsky has a strong track record in securities litigation, winning significant recoveries for shareholders over 20 years.

Last updated: Jan 9, 2026